Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review
Addiction and Health · 2025
DOI: 10.34172/ahj.1527 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Addiction and Health, 2025. Verfasst von Zahra Oskouei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Pregabalin (PGB), a gabapantinoid drug, which is commonly prescribed by physicians and some patients abuse it, can lead to seizure. Pregabalin-induced seizures (PGBIS) and their risk factors were systematically reviewed.
Methods
The databases were searched from January 1, 2011, to August 1, 2022. Studies that reported PGBIS were included. The records were assessed according to the PRISMA-P protocol.
Results
From a total of 224 records, 11 studies were included, comprising four cross-sectional studies and seven case reports. The data from the cross-sectional studies were notably limited. Seven studies documented nine cases (five females and four males), with a median age of 51 years (ranging from 16 to 65). PGB was used for therapeutic purposes, abuse, and suicide attempts. One case had kidney dysfunction. A significant number of cases used PGB with other drugs. There was no difference between the ingested dose of PGB in men (2700 and 4200 mg) and women (3000, 1200, 3825, and 1200 mg). All cases had normal renal function, except for one case.
Conclusion
PGBIS is not common. However, it was reported for all purposes of PGB consumption. No specific risk factor for PGBIS was found. It was more commonly reported in females, patients who consumed high doses of PGB (>1200 mg), patients who ingested multiple drugs, and patients with renal insufficiency. The dosages used for therapeutic purposes were much lower than in the other two groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Community Medicine Department, Mashhad University of Medical Sciences, Mashhad, Iran.
- Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Zahra Oskouei, Mohammad Moshiri, Amene Raouf-Rahmati, Ahmad Nemati, Mehri Bemani Naeini, Hamid Jomehpour, Ali Roohbakhsh, Zahra Salmasi, Leila Etemad
Zitieren
APA
Oskouei, Z., Moshiri, M., Raouf-Rahmati, A., Nemati, A., Bemani Naeini, M., Jomehpour, H., Roohbakhsh, A., Salmasi, Z., & Etemad, L. (2025). Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review. Addiction and Health. https://doi.org/10.34172/ahj.1527
Vancouver
Oskouei Z, Moshiri M, Raouf-Rahmati A, Nemati A, Bemani Naeini M, Jomehpour H, et al. Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review. Addiction and Health. 2025. doi:10.34172/ahj.1527
BibTeX
@article{Oskouei2025,
author = {Oskouei, Zahra and Moshiri, Mohammad and Raouf-Rahmati, Amene and Nemati, Ahmad and Bemani Naeini, Mehri and Jomehpour, Hamid and Roohbakhsh, Ali and Salmasi, Zahra and Etemad, Leila},
title = {Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review},
journal = {Addiction and Health},
year = {2025},
doi = {10.34172/ahj.1527}
}
EUVIMED